Phase Angle, Inflammation, and Sarcopenia in Late Postoperative Roux-En-Y Gastric Bypass.
Gisele FlorêncioAglécio SouzaÉlinton Adami ChaimAllan SantosLouise DuranCamila CarvalhoSarah Monte AlegrePublished in: Journal of clinical medicine (2023)
Sarcopenic obesity is characterized by a disproportion between the amount of muscle to fat. Contrary to most studies evaluating parameters related to sarcopenic obesity in the elderly, this study aims to evaluate the phase angle (PhA) and sarcopenia in young individuals pre- and post-Roux-en-Y gastric bypass. A total of 69 volunteers (46 women and 23 men; 38.5 ± 8.1 years) participated in this study. Body composition and PhA were assessed using BIA. Sarcopenia was assessed using a handgrip strength test (HGS) and gait speed (GS), and appendicular lean mass (ALM) was assessed using Dual Energy X-ray Absorptiometry (DXA). The PhA was significantly lower ( p < 0.0007) and the resistance (R) significantly higher ( p = 0.0026) in the postoperative group. HGS was negatively correlated with R (r = -0.63669; p < 0.0001), hs-CRP (r = -0.45436; p = 0.0197), and leptin (r = -0.46505; p = 0.0043). GS was negatively correlated with R (r = -0.36220; p = 0.0254), and ALM was negatively correlated with reactance (r = -0.49485; p = 0.0034) and R (r = -0.65797; p ≤ 0.0001). PhA and other components of BIA provide a good correlation with sarcopenia, especially regarding the reduction in muscle function, in an early form, in individuals in the pre- and postoperative period of gastric bypass.
Keyphrases
- roux en y gastric bypass
- gastric bypass
- weight loss
- body composition
- dual energy
- skeletal muscle
- obese patients
- bone mineral density
- bariatric surgery
- computed tomography
- patients undergoing
- insulin resistance
- community dwelling
- high resolution
- metabolic syndrome
- resistance training
- type diabetes
- adipose tissue
- weight gain
- magnetic resonance
- polycystic ovary syndrome
- image quality
- mass spectrometry
- magnetic resonance imaging
- oxidative stress
- contrast enhanced
- fatty acid
- drug induced
- case control